Haohai Biotech (688366.SH) plans to buy 19.8% of Ruiji Biotech's shares

Zhitong Finance App News, Haohai Biotech (688366.SH) announced that the company plans to use its own capital of RMB 38.3515 million to transfer the total shares of Jiangxi Ruiji Biotechnology Co., Ltd. (hereinafter referred to as “Ruiji Biotech”) held by Miao Jiuchang and Miao Chunyun, accounting for 19.8% of Ruiji Biotech's total share capital.

Regis Biotech was established in 2002. Its main business is the production and sale of biological amniotic membranes. The main products and services are uneven amniotic membrane products, biological orthopedic amniotic membrane products, and wet bioamniotic membrane products. They are mainly used in orthopedic and ophthalmology fields, including repair after tendon injury, repair of superficial ocular burns and wounds, and implantation and support after lacrimal duct obstruction is detected. By investing in the target company and obtaining distribution rights for the target company's products in China, the company entered the bioamniotic film, a high-value medical device circuit, effectively complementing the company's existing product portfolio and expanding business coverage in the field of ophthalmology and orthopedics. At the same time, the amniotic membrane material possessed by the target company has anthropogenic biological characteristics, providing an important technical and material foundation for the research and development of the company's related business in the field of regenerative medicine and tissue engineering, and is expected to promote subsequent product innovation and technological upgrading.